Previous Close | 1.5900 |
Open | 1.5601 |
Bid | 1.5200 x 1800 |
Ask | 1.6600 x 1100 |
Day's Range | 1.5200 - 1.6900 |
52 Week Range | 1.3600 - 4.9900 |
Volume | |
Avg. Volume | 23,016 |
Market Cap | 56.843M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 17.67 |
EPS (TTM) | 0.0900 |
Earnings Date | Feb 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for QLI
The nature of investing is that you win some, and you lose some. And there's no doubt that Qilian International Holding...
Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the fiscal year ended September 30, 2021.
Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provincial Drug Administration on January 14, 2022 for the sale of its newly developed nitrofurantoin enteric-coated tablets. This indicates that the Company officially become the first enterprise in Gansu Province with the Gansu Provincial Drug Administ